DANISH-CRTHot Line 10Devices & Arrhythmias
Targeted Left Ventricular Lead Placement in Cardiac Resynchronisation Therapy
Targeted left ventricular lead placement for cardiac resynchronisation therapy in heart failure
Presenting authorJens Cosedis NielsenElectrophysiology · Statens Serum InstitutJens Cosedis Nielsen is a Professor of Cardiology at the Department of Clinical Medicine, Aarhus University, and Co-Director at the Department of Cardiology, Aarhus University Hospital. He has been involved in committees of the European Heart Rhythm Association and the European Society of Cardiology since 2011. He chaired the task force on cardiac pacing and cardiac resynchronization therapy for the 2021 ESC Guidelines.
Overview
Pending targeted LV lead results leave CRT optimization unproven; clinicians should await ESC 2026 data before changing implantation practice.
Key result
Targeted left ventricular lead placement for cardiac resynchronisation therapy in heart failure currently has pending results from the ESC Congress 2026 late-breaking trial.
Discussion
Expert reaction lands here the moment DANISH-CRT reports.
Expert takes
The DANISH-CRT trial is a large randomized trial (set to enrol 1,000 patients) testing whether electrically guided positioning of the left ventricular lead during cardiac resynchronization therapy reduces hospitalization for heart failure or death compared to standard care lead placement. The source material contains very limited direct coverage of DANISH-CRT itself; it is primarily mentioned as a forthcoming trial in the context of the ElectroCRT pilot study results. The source material is dominated by coverage of the parent DANISH trial (on ICDs in non-ischemic heart failure) and related sub-studies, not DANISH-CRT specifically.
Key Points
- Investigation evaluates targeted left ventricular lead placement strategies designed to optimize cardiac resynchronisation therapy outcomes in patients diagnosed with heart failure.
- Clinical trial details presented at ESC Congress 2026 evaluate cardiac pacing parameters and procedural outcomes, with definitive clinical trial results currently pending publication.
- Clinical trial protocol highlights potential improvements in ventricular synchrony and heart failure management through anatomically targeted cardiac resynchronisation therapy leads.
Main Result
Absolute Event Rate: 0% vs 0%